Ramucirumab showed a significant survival benefit in patients with advanced HCC and a baseline AFP ≥ 400 mg/mL following previous sorafenib treatment.
Final analysis of phase III trial showed no significant improvement with pembrolizumab vs paclitaxel in OS, PFS, or response in patients with previously treated gastric/GEJ cancer and PD-L1 CPS ≥ 1.
Lenvatinib combined with pembrolizumab showed promising antitumor activity with no unexpected toxicities in this early-stage study.
A modified FOLFIRINOX regimen was superior to gemcitabine after resection of pancreatic cancer, with significantly prolonged disease-free, metastasis-free, and overall survivals.
Neoadjuvant treatment extended OS, DFS, and improved R0 resection rate vs adjuvant treatment in patients undergoing surgery for pancreatic cancer.